June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Evaluation of the effects of RB-35 on the viability and growth of a corneal epithelium cell line
Author Affiliations & Notes
  • blanca elizabeth martinez baez
    Cornea, Asociación para Evitar la Ceguera en México "Hospital Dr. Luis Sánchez Bulnes" IAP, Ciudad de Mexico, D.f., Mexico
  • Rosario Gulías-Cañizo
    Cornea, Asociación para Evitar la Ceguera en México "Hospital Dr. Luis Sánchez Bulnes" IAP, Ciudad de Mexico, D.f., Mexico
  • Valeria Sanchez-Huerta
    Cornea, Asociación para Evitar la Ceguera en México "Hospital Dr. Luis Sánchez Bulnes" IAP, Ciudad de Mexico, D.f., Mexico
  • Federico Castro Muñoz-Ledo
    Cornea, Asociación para Evitar la Ceguera en México "Hospital Dr. Luis Sánchez Bulnes" IAP, Ciudad de Mexico, D.f., Mexico
  • Lorena Zendejas Reyes
    Cornea, Asociación para Evitar la Ceguera en México "Hospital Dr. Luis Sánchez Bulnes" IAP, Ciudad de Mexico, D.f., Mexico
  • Footnotes
    Commercial Relationships   blanca elizabeth martinez baez, None; Rosario Gulías-Cañizo, None; Valeria Sanchez-Huerta, None; Federico Castro Muñoz-Ledo, None; Lorena Zendejas Reyes, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 967. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      blanca elizabeth martinez baez, Rosario Gulías-Cañizo, Valeria Sanchez-Huerta, Federico Castro Muñoz-Ledo, Lorena Zendejas Reyes; Evaluation of the effects of RB-35 on the viability and growth of a corneal epithelium cell line. Invest. Ophthalmol. Vis. Sci. 2017;58(8):967.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : RB-35 has shown to possess antioxidant properties due to its free radical scavenging activities and its protective effects against lipid peroxidation. Since oxidative damage plays a major role in many ocular surface diseases, we aimed to evaluate the effects of RB-35 in a corneal epithelium cell line as preliminary evidence of its therapeutic potential.

Methods : A rabbit corneal epithelium cell line was used, RCE-1(5T5), which reproduces in vitro the differentiation and proliferation processes normally present in primary cultures of corneal epithelium.
The experimental strategy included: Colony forming assay to evaluate cell growth, flow cytometry to evaluate cell viability and immunofluorescence to evaluate cell phenotype. All experiments were performed in triplicate.
In the colony forming assay, the cells are seeded with the standard density for a 35 mm plate (3 x 104) on day 0; on day 1 control cells receive corneal medium + EGF and treated cells receive corneal medium + EGF + RB-35 at different concentrations (10 µM, 20 µM, 30 µM, 50 µM, 100 µM). On day 3, cells are harvested and reseeded with a seeding density of 500 cells per 60 mm plate, and the growth is evaluated on a daily basis until the culture forms colonies. At this point, colonies are stained with rhodamine.
To evaluate cell viability,we used 7-aminoactinomycin D, a fluorescent intercalator that undergoes a spectral shift upon association with DNA, which stains non-viable cells. These experiments were analyzed by flowcytometry.
We also performed the immunofluorescence staining protocol for keratin 3, a marker of terminal differentiation specific of corneal epithelial cells, to evaluate cell characteristics.

Results : We demonstrate a colony forming efficiency similar to the control, which rules out an anti-proliferative effect on cell growth. The percentages of colony forming efficiency between control cells and treated cells did not show statistical significance. Moreover, in the viability assay, we observed a statistical significant difference favoring RB-35.

Conclusions : RB-35 does not induce cytotoxic effects in a concentration range of 10 to 100 µM, and it demonstrates a protective effect evidenced by reduction of apoptosis without inducing cell phenotypic changes. These results give the first positive evidence to continue evaluating RB-35 as a potential treatment for ocular conditions.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×